Addressing the Challenges in Acute Myeloid Leukemia Treatment: Clinical Updates and Strategies to Optimize Delivery of Care

Addressing the Challenges in Acute Myeloid Leukemia Treatment: Clinical Updates and Strategies to Optimize Delivery of Care

A 1.5-hour Accredited On-Demand Virtual Symposium Presented at AMCP Annual 2021

Moderator
Robert Mancini, PharmD, BCOP, FHOPA
BMT Pharmacy Program Coordinator & PGY-2 Oncology Residency Director
St. Luke’s Cancer Institute
Boise, Idaho

Clinical Adjunct Instructor – Oncology
Idaho State University College of Pharmacy
Pocatello, Idaho

Faculty Presenters
Colleen Timlin, PharmD, BCOP
Clinical Pharmacy Specialist
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Yuqian Liu, PharmD, RPh
Director, Specialty Clinical Solutions
Magellan Rx Management
Middletown, Rhode Island
 
Program Description
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and has a poor prognosis, with an overall 5-year survival rate of AML in adults of approximately 25%. Hypomethylating agents and other novel therapies including several oral oncolytics have offered alternative treatment options to poorly tolerated intense induction chemotherapy for patients older than 60 years. Despite these advances, prognosis remains poor for this patient population. New maintenance therapy regimens for some patients with AML have demonstrated clinical benefit. Managed care professionals and pharmacists should be familiar with emerging agents, especially oral therapy options, and consider their place in the AML treatment paradigm alongside updated recommendations for first-line therapies. The expert panelists will discuss additional challenges in treating older patients with AML that have been exacerbated by the COVID-19 pandemic and examine approaches managed care professionals can take to develop and implement clinical pathways for treatment of AML.

Target Audience: Managed care and oncology pharmacists
Type of Activity: Application
Release date: April 28, 2021
Expiration date: April 28, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Examine recent FDA approvals and clinical updates to investigational therapies for the treatment of acute myeloid leukemia (AML)
• Analyze maintenance regimens with hypomethylating agents and the results from clinical trials
• Identify challenges associated with treatment of older patients with AML, particularly during the COVID-19 pandemic
• Employ the key criteria and factors for optimal clinical pathway development, implementation, and use in treatment for patients with AML

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-168-H01-P. The activity is available for CE credit through April 28, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Robert Mancini, PharmD, BCOP, FHOPA, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: GlaxoSmithKline

• Speakers Bureau: Takeda Pharmaceuticals, GlaxoSmithKline

Yuqian Liu, PharmD, RPh, and Colleen Timlin, PharmD, BCOP, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms